SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Nucl Med. 2008; 49 (Supplement 1):350P
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Hugentobler, A.
Right arrow Articles by Agostini, D.
PubMed
Right arrow Articles by Hugentobler, A.
Right arrow Articles by Agostini, D.

Oncology-Clinical Diagnosis: Solid Tumors

Clinical Diagnosis-Solid Tumors Posters

Impact of 99mTc-depreotide (Neospect) to screen somatostatin receptors (SSTR) in hepatocellular carcinoma (HCC): A comparison with 111 In-DTPA-octreotide (Octreoscan)

Alexis Hugentobler1, Fredericke Dumont1, Isabelle Ollivier1, Sylvie Costo1, Vincent Dunet1, Eric NGuyenKhac1, Thong Dao1, Laurence Chiche1, Damien Peyronnet1 and Denis Agostini1

1 CHU Cote de Nacre, Caen, France

1481

Objectives: To assess Neospect ability to screen SSTR in HCC in comparison with Octreoscan. Octreotide therapy efficiency in HCC seems related to SSTR overexpression by Octreoscan. Neospect has very high affinity for SSTR subtypes 2, 3, and 5 and has never been tested in HCC SSTR overexpression screening.

Methods: 13 patients with (11 M-2 F : 68.1 ± 9 yrs, 11 cirrhotics) HCC ≥ 3 cm based on either histology or Barcelona criteria were included in a prospective randomized study. Patients underwent both scintigraphies at 10 days maximum delay on a SIEMENS ecamTM double head gamma camera. Late SPECT acquisitions were performed : 6H post injection(p.i) for Neospect and 24H p.i for Octreoscan. SPECT images were fused images with abdominal CT or MRI for precise tumor location. Evaluation criteria for SSTR overexpression was an uptake of HCC superior to the surrounding liver.

Results: Octreoscan® HCC uptake was found in 5/13 patients (38.5 %) vs 8/13 (61.5 %) with Neospect (p=0.239). Neospect revealed more HCC nodules in more patients than Octreoscan did. 5 patients showed uptake with Octreoscan vs 8 with Neospect. At site level 8 HCC nodules were detected by Octreoscan vs 13 by Neospect. All HCC nodules detected with Octreoscan® were also detected with Neospect except one in a patient who had another HCC positive nodule with Neospect.

Conclusions: Neospect imaging is almost as efficient as Octreoscan in HCC SSTR screening. Neospect interest in HCC management should be evaluated as new somatostatin analogues therapy (SSTR2, SSTR3 SSTR5) are under development.





Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Hugentobler, A.
Right arrow Articles by Agostini, D.
PubMed
Right arrow Articles by Hugentobler, A.
Right arrow Articles by Agostini, D.